Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Consolidated Net Income: 2020-2024

Historic Consolidated Net Income for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to -$72.7 million.

  • Monte Rosa Therapeutics' Consolidated Net Income fell 13.50% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 117.52%. This contributed to the annual value of -$72.7 million for FY2024, which is 46.27% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Consolidated Net Income of -$72.7 million as of FY2024, which was up 46.27% from -$135.4 million recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Consolidated Net Income ranged from a high of -$25.8 million in FY2020 and a low of -$135.4 million during FY2023.
  • For the 3-year period, Monte Rosa Therapeutics' Consolidated Net Income averaged around -$105.5 million, with its median value being -$108.5 million (2022).
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Consolidated Net Income crashed by 148.62% in 2021, and later soared by 46.27% in 2024.
  • Yearly analysis of 5 years shows Monte Rosa Therapeutics' Consolidated Net Income stood at -$25.8 million in 2020, then slumped by 148.62% to -$64.1 million in 2021, then tumbled by 69.34% to -$108.5 million in 2022, then dropped by 24.75% to -$135.4 million in 2023, then soared by 46.27% to -$72.7 million in 2024.